Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
7-Day Reset Make the necessary adjustments and plan for 7 days
The public booking flow does not ask a BMI or eligibility-gating weight question, does not collect a medical history, does not ask about current medications or allergies, does not include a dedicated MEN-2 or medullary thyroid cancer family-history screen, does not ask the eating-disorder question, does not check pregnancy or breastfeeding status, does not include a validated mental-health instrument, and does not ask about substance or alcohol use
Gallbladder In the SCALE-trial, high-dose liraglutide for the treatment of obesity was associated with an increased risk of gallbladder events compared to placebo (2.5% versus 1.0% of patients, respectively) ( versus 0.1% with placebo), while the risk of cholecystitis was similar (data derived from the summary of product characteristics (SmPC) ( Initially the gallbladder events were attributed to GLP-1RA-induced weight loss, as for example in the SCALE and LEADER trials, the patients with gallbladder events had more than average weight loss ( Cardiovascular All GLP-1RAs increase heart rate, and this is not different for semaglutide
Our team is here to help you: Review your current plan benefits Understand your coverage options Identify cost-saving opportunities Determine whether a different plan may better fit your needs If you have questions or want help reviewing your coverage, click here to reach out
The MOMENTUM Phase II obesity trial demonstrated compelling weight loss and a favorable safety profile
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
